Cell-penetrating R9 peptide-modified DNA origami nanostructures, delivered via nebulizer directly to the lungs, reduced dangerous inflammation in alveolar macrophages and alleviated acute lung injury in mice.
Enhanced macrophage uptake + M2 polarizationR9 CPP modification drove preferential uptake by alveolar macrophages and shifted them from pro-inflammatory (M1) to anti-inflammatory (M2) phenotype, breaking the inflammation cascade
What the researchers found
R9 peptide-modified triangular DNA origami nanostructures, delivered by nebulization, effectively targeted alveolar macrophages, scavenged ROS, promoted M2 polarization, and reduced lung inflammation in an ALI mouse model.
Why it matters
Acute lung injury and ARDS have limited treatment options and high mortality rates, as highlighted during COVID-19. A nebulizable therapy that directly targets the lung macrophages driving inflammation — and can scavenge the damaging oxidants — could provide early intervention before irreversible lung damage occurs.
The numbers in context
R9 peptide-modified triangular DNA origami (tDONs-R9); nebulized delivery to deep lung; targeted alveolar macrophages.
How the study worked
Designed and synthesized tDONs-R9 using DNA origami technology with R9 CPP modification. Tested macrophage uptake and polarization in vitro, then evaluated therapeutic efficacy via nebulized inhalation in an LPS-induced ALI mouse model. Measured ROS levels, cytokine expression, and neutrophil infiltration.
Who was studied
Mice with induced acute lung injury
What this study cannot tell us
Mouse study using LPS-induced ALI — this model doesn't perfectly replicate human ALI/ARDS. Manufacturing DNA origami at clinical scale remains a significant challenge. Long-term safety of DNA nanostructures accumulating in lung tissue is unknown. Only one disease model and one time point were tested.
How to read the evidence
Preliminary — single animal study demonstrating proof-of-concept in one mouse ALI model. Promising results but far from clinical application.
When this study was published
Published in 2024 in Nano Letters, a top-tier nanotechnology journal.
The bigger picture
This study sits at the intersection of three cutting-edge technologies: DNA origami nanotechnology, cell-penetrating peptides, and inhaled drug delivery. The combination creates a platform that could extend beyond ALI to other inflammatory lung diseases like COPD, asthma, and pulmonary fibrosis. The programmable nature of DNA origami means the nanostructures could potentially be loaded with additional therapeutic agents.
Questions still open
- Can DNA origami nanostructures be produced at the scale and consistency needed for clinical use?
- How do tDONs-R9 perform in more clinically relevant ALI models, such as ventilator-induced or sepsis-induced lung injury?
- Could this platform be adapted to carry additional drugs or anti-inflammatory agents for enhanced therapeutic effect?
Common questions
What is DNA origami and how can it treat lung disease?
Why use a nebulizer instead of an injection?
Read the original research
Nebulized Inhalation of Peptide-Modified DNA Origami To Alleviate Acute Lung Injury.
Nano letters, 24(20), 6102-6111
Citation
Wang, Haiyan; Jiao, Yunfei; Ma, Shuaijing; Li, Zhuoting; Gong, Jintao; Jiang, Qiao; Shang, Yingxu; Li, Hongling; Li, Jing; Li, Na; Zhao, Robert Chunhua; Ding, Baoquan. (2024). Nebulized Inhalation of Peptide-Modified DNA Origami To Alleviate Acute Lung Injury.. Nano letters, 24(20), 6102-6111. https://doi.org/10.1021/acs.nanolett.4c01222